[조사자료] 글로벌 원료 의약품 CDMO 시장 (2023-2030) : 강력한 API, 항체 약물 접합체

■ 영문 제목 : Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product (Highly Potent API, Antibody Drug Conjugate), By Synthesis, By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2023 - 2030
	■ 상품코드 : GRV23NOV025 ■ 조사/발행회사 : Grand View Research ■ 발행일 : 2023년 9월 ■ 페이지수 : 150 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (납기:3일) ■ 조사대상 지역 : 세계 ■ 산업 분야 : 제약

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User (1인 열람용)	USD5,950 ⇒환산￦8,032,500	견적의뢰/주문/질문
Multi User (5인 열람용)	USD6,950 ⇒환산￦9,382,500	견적의뢰/주문/질문
Global/corporate License (기업 열람용)	USD8,950 ⇒환산￦12,082,500	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

글로벌 원료 의약품 CDMO 시장의 성장 및 동향
Grand View Research사의 최신 보고서에 따르면, 세계의 원료 의약품 CDMO 시장 규모는 2030년까지 1,563억 달러에 달할 것으로 예상되며, 2023년부터 2030년까지 연평균 6. 9%의 성장률로 확대될 전망입니다. 제약 R&D 투자 증가, 특허 만료, 제네릭 의약품 수요 증가, 아웃소싱을 촉진하는 생물학적 기술 혁신이 시장을 견인하는 요인입니다.

저분자 의약품의 증가, 원료의약품(API)의 복잡성 증가, 비용 절감의 필요성이 제약 분야 아웃소싱 서비스의 급속한 확대에 기여하고 있습니다. CDMO(위탁개발 및 제조대행) 분야에서 글로벌 사업 전개와 규모 확장을 실현한 기업은 극소수에 불과하며, 아직은 단편적인 수준입니다. 또한 많은 기업들이 원료와 제제의 통합 소스로서 원스톱 샵 솔루션을 제공하고 있습니다.

의료 산업은 역동적인 변화의 과정에 있으며, 급속한 기술 발전(자동화, AI 등), CRO/CMO/CDMO 수요, 연구 투자 증가 등의 요인이 의료 시장에 영향을 미치고 있습니다. 활동의 아웃소싱은 운영 효율성 향상, 지리적 입지 확대, 자원 비용 절감, 치료 전문성 확보, 온디맨드 서비스 강화 등 많은 제약회사에 이익을 가져다주었습니다.

코로나19 팬데믹은 인공호흡이 필요한 중증 환자 관리에 필요한 의약품에 대한 수요가 크게 증가한 것에서 알 수 있듯이 원료의약품 제조업체에 전례 없는 기대를 안겨주었습니다. 이에 따라 급격한 생산량 증가가 필요해졌고, 원료 의약품 CDMO는 의약품 공급을 유지하기 위해 적응력을 갖춰야 했습니다. 새로운 치료법에 대한 전 세계적인 수요 증가와 팬데믹 이후 임상 연구 증가는 향후 몇 년간 시장을 뒷받침할 것으로 예상됩니다.

원료 의약품 CDMO 시장 보고서 주요 내용

- 전통적인 원료의약품 부문이 2022년 39. 8%의 가장 큰 매출 점유율을 차지하며 시장을 주도할 것으로 예상됩니다.

- 혁신 의약품 부문은 2022년 73. 7%의 매출 점유율을 차지할 것으로 예상됩니다. 이는 주로 새로운 분자체에 대한 FDA 승인 증가와 혁신적 API 기업들의 연구개발에 대한 집중도가 높아졌기 때문입니다.

- 2022년 매출 점유율은 암 분야가 35. 5%로 가장 높습니다. 이는 암 치료용 고활성 API에 대한 수요 증가에 기인합니다.

- 바이오테크놀로지 분야는 만성질환 및 감염성 질환 치료에 바이오의약품이 많이 사용되고 있어 예측 기간 동안 7.0%의 빠른 성장이 예상됩니다.

- 임상 워크플로우 분야는 예측 기간 동안 가장 빠른 CAGR 7. 3%로 성장할 것으로 예상됩니다. 원료의약품 수요를 뒷받침하는 임상연구의 증가가 이 분야의 성장을 촉진하는 주요 요인 중 하나입니다.

- 아시아 태평양 지역은 예측 기간 동안 가장 빠른 CAGR 9. 1%를 기록할 것으로 예상됩니다. 인도, 중국 등 개발도상국에서는 제약회사 및 위탁 생산 기관의 수가 크게 증가하고 있기 때문에 이 지역은 가까운 장래에 유럽과 북미를 추월할 가능성이 높다고 전했습니다.

■ 보고서 개요

Chapter 1. 조사 방법 및 범위
Chapter 2. 개요
Chapter 3. 시장 변수/동향/범위
Chapter 4. 세계의 원료 의약품 CDMO 시장 : 제품별 분석
Chapter 5. 세계의 원료 의약품 CDMO 시장 : 합성별 분석
Chapter 6. 세계의 원료 의약품 CDMO 시장 : 약물별 분석
Chapter 7. 세계의 원료 의약품 CDMO 시장 : 워크플로우별 분석
Chapter 8. 세계의 원료 의약품 CDMO 시장 : 용도별 분석
Chapter 9. 세계의 원료 의약품 CDMO 시장 : 지역별 분석
Chapter 10. 경쟁 현황

■ 보고서 목차

Table of contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Synthesis
1.1.3. Drug
1.1.4. Application
1.1.5. Workflow
1.1.6. Regional scope
1.1.7. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.9.3. Objective 3
1.9.4. Objective 4
Chapter 2. Executive Summary
2.1. Market Outlook
Chapter 3. Active Pharmaceutical Ingredients CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Increasing pharmaceutical R&D investment
3.3.1.2. Rising demand for generic drugs
3.3.1.3. Patent expiration
3.3.1.4. Expanding consumption of biopharmaceuticals
3.3.2. Market Restraint Analysis
3.3.2.1. Compliance issues while outsourcing
3.3.3. COVID-19 Impact & Recovery Analysis
3.3.4. Industry Analysis – Porter’s Five Forces
3.3.5. PESTLE Analysis
Chapter 4. Active Pharmaceutical Ingredients CDMO Market: Product Segment Analysis
4.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
4.2. Active Pharmaceutical Ingredients CDMO Market: Product Market Share Analysis, 2022 & 2030
4.3. Traditional Active Pharmaceutical Ingredient (Traditional API)
4.3.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market, 2018 – 2030 (USD Million)
4.4. Highly Potent Active Pharmaceutical Ingredient (HP-API)
4.4.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market, 2018 – 2030 (USD Million)
4.5. Antibody Drug Conjugate (ADC)
4.5.1. Antibody Drug Conjugate (ADC) Market, 2018 – 2030 (USD Million)
4.6. Others
4.6.1. Others Market, 2018 – 2030 (USD Million)
Chapter 5. Active Pharmaceutical Ingredients CDMO Market: Synthesis Segment Analysis
5.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
5.2. Active Pharmaceutical Ingredients CDMO Market: Synthesis Market Share Analysis, 2022 & 2030
5.3. Synthetic
5.3.1. Synthetic Market, 2018 – 2030 (USD Million)
5.4. Biotech
5.4.1. Biotech Market, 2018 – 2030 (USD Million)
Chapter 6. Active Pharmaceutical Ingredients CDMO Market: Drug Segment Analysis
6.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
6.2. Active Pharmaceutical Ingredients CDMO Market: Drug Market Share Analysis, 2022 & 2030
6.3. Innovative
6.3.1. Innovative Market, 2018 – 2030 (USD Million)
6.4. Generic
6.4.1. Generic Market, 2018 – 2030 (USD Million)
Chapter 7. Active Pharmaceutical Ingredients CDMO Market: Workflow Segment Analysis
7.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
7.2. Active Pharmaceutical Ingredients CDMO Market: Workflow Market Share Analysis, 2022 & 2030
7.3. Clinical
7.3.1. Clinical Market, 2018 – 2030 (USD Million)
7.4. Commercial
7.4.1. Commercial Market, 2018 – 2030 (USD Million)
Chapter 8. Active Pharmaceutical Ingredients CDMO Market: Application Segment Analysis
8.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
8.2. Active Pharmaceutical Ingredients CDMO Market: Application Market Share Analysis, 2022 & 2030
8.3. Oncology
8.3.1. Oncology Market, 2018 – 2030 (USD Million)
8.4. Hormonal
8.4.1. Hormonal Market, 2018 – 2030 (USD Million)
8.5. Glaucoma
8.5.1. Glaucoma Market, 2018 – 2030 (USD Million)
8.6. Cardiovascular
8.6.1. Cardiovascular Market, 2018 – 2030 (USD Million)
8.7. Diabetes
8.7.1. Diabetes Market, 2018 – 2030 (USD Million)
8.8. Others
8.8.1. Others Market, 2018 – 2030 (USD Million)
Chapter 9. Active Pharmaceutical Ingredients CDMO Market: Regional Analysis
9.1. Active Pharmaceutical Ingredients CDMO Regional market share analysis, 2022 & 2030
9.2. North America
9.2.1. North America Market estimates and forecast, 2018 – 2030
9.2.2. U.S.
9.2.2.1. U.S. Market estimates and forecast, 2018 – 2030
9.2.3. Canada
9.2.3.1. Canada Market estimates and forecast, 2018 – 2030
9.3. Europe
9.3.1. Europe Market estimates and forecast, 2018 – 2030
9.3.2. UK
9.3.2.1. UK Market estimates and forecast, 2018 – 2030
9.3.3. Germany
9.3.3.1. Germany Market estimates and forecast, 2018 – 2030
9.3.4. France
9.3.4.1. France Market estimates and forecast, 2018 – 2030
9.3.5. Italy
9.3.5.1. Italy Market estimates and forecast, 2018 – 2030
9.3.6. Spain
9.3.6.1. Spain Market estimates and forecast, 2018 – 2030
9.3.7. Denmark
9.3.7.1. Denmark Market estimates and forecast, 2018 – 2030
9.3.8. Sweden
9.3.8.1. Sweden Market estimates and forecast, 2018 – 2030
9.3.9. Norway
9.3.9.1. Norway Market estimates and forecast, 2018 – 2030
9.4. Asia Pacific
9.4.1. Asia Pacific Market estimates and forecast, 2018 – 2030
9.4.2. Japan
9.4.2.1. Japan Market estimates and forecast, 2018 – 2030
9.4.3. China
9.4.3.1. China Market estimates and forecast, 2018 – 2030
9.4.4. India
9.4.4.1. India Market estimates and forecast, 2018 – 2030
9.4.5. South Korea
9.4.5.1. South Korea Market estimates and forecast, 2018 – 2030
9.4.6. Australia
9.4.6.1. Australia Market estimates and forecast, 2018 – 2030
9.4.7. Thailand
9.4.7.1. Thailand Market estimates and forecast, 2018 – 2030
9.5. Latin America
9.5.1. Latin America Market estimates and forecast, 2018 – 2030
9.5.2. Brazil
9.5.2.1. Brazil Market estimates and forecast, 2018 – 2030
9.5.3. Mexico
9.5.3.1. Mexico Market estimates and forecast, 2018 – 2030
9.5.4. Argentina
9.5.4.1. Argentina Market estimates and forecast, 2018 – 2030
9.5.5. Colombia
9.5.5.1. Colombia Market estimates and forecast, 2018 – 2030
9.5.6. Chile
9.5.6.1. Chile Market estimates and forecast, 2018 – 2030
9.6. MEA
9.6.1. MEA Market estimates and forecast, 2018 – 2030
9.6.2. South Africa
9.6.2.1. South Africa Market Estimates and forecast, 2018 – 2030
9.6.3. Saudi Arabia
9.6.3.1. Saudi Arabia Market estimates and forecast, 2018 – 2030
9.6.4. UAE
9.6.4.1. UAE Market estimates and forecast, 2018 – 2030
9.6.5. Kuwait
9.6.5.1. Kuwait Market estimates and forecast, 2018 – 2030
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Strategy Mapping
10.3. Company Profiles/Listing
10.3.1. Cambrex Corporation
10.3.1.1. Overview
10.3.1.2. Financial Performance
10.3.1.3. Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Recipharm AB
10.3.2.1. Overview
10.3.2.2. Financial Performance
10.3.2.3. Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. Thermo Fisher Scientific Inc. (Pantheon)
10.3.3.1. Overview
10.3.3.2. Financial Performance
10.3.3.3. Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Samsung Biologics
10.3.4.1. Overview
10.3.4.2. Financial Performance
10.3.4.3. Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Lonza
10.3.5.1. Overview
10.3.5.2. Financial Performance
10.3.5.3. Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Catalent, Inc.
10.3.6.1. Overview
10.3.6.2. Financial Performance
10.3.6.3. Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. Siegfried Holding AG
10.3.7.1. Overview
10.3.7.2. Financial Performance
10.3.7.3. Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Piramal Pharma Solutions
10.3.8.1. Overview
10.3.8.2. Financial Performance
10.3.8.3. Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Boehringer Ingelheim
10.3.9.1. Overview
10.3.9.2. Financial Performance
10.3.9.3. Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. CordenPharma International
10.3.10.1. Overview
10.3.10.2. Financial Performance
10.3.10.3. Service Benchmarking
10.3.10.4. Strategic Initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 4 Global active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 5 Global active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 6 Global active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 7 Global active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 8 Global active pharmaceutical ingredient CDMO market, by region, 2018 - 2030 (USD Million)
Table 9 North America active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 10 North America active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 11 North America active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 12 North America active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 13 North America active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 14 North America active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 15 U.S. active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 16 U.S. active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 17 U.S. active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 18 U.S. active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 19 U.S. active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 20 Canada active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 21 Canada active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 22 Canada active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 23 Canada active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 24 Canada active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 25 Europe active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 26 Europe active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 27 Europe active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 28 Europe active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 29 Europe active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 30 Europe active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 31 Germany active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 32 Germany active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 33 Germany active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 34 Germany active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 35 Germany active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 36 UK active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 37 UK active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 38 UK active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 39 UK active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 40 UK active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 41 France active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 42 France active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 43 France active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 44 France active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 45 France active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 46 Italy active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 47 Italy active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 48 Italy active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 49 Italy active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 50 Italy active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 51 Spain active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 52 Spain active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 53 Spain active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 54 Spain active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 55 Spain active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 56 Denmark active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 57 Denmark active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 58 Denmark active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 59 Denmark active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 60 Denmark active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 61 Sweden active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 62 Sweden active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 63 Sweden active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 64 Sweden active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 65 Sweden active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 66 Norway active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 67 Norway active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 68 Norway active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 69 Norway active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 70 Norway active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 71 Asia Pacific active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 72 Asia Pacific active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 73 Asia Pacific active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 74 Asia Pacific active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 75 Asia Pacific active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 76 Asia Pacific active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 77 Japan active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 78 Japan active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 79 Japan active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 80 Japan active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 81 Japan active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 82 China active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 83 China active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 84 China active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 85 China active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 86 China active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 87 India active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 88 India active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 89 India active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 90 India active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 91 India active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 92 Australia active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 93 Australia active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 94 Australia active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 95 Australia active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 96 Australia active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 97 South Korea active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 98 South Korea active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 99 South Korea active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 100 South Korea active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 101 South Korea active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 102 Thailand active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 103 Thailand active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 104 Thailand active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 105 Thailand active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 106 Thailand active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million
Table 107 Latin America active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 108 Latin America active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 109 Latin America active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 110 Latin America active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 111 Latin America active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 112 Latin America active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 113 Brazil active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 114 Brazil active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 115 Brazil active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 116 Brazil active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 117 Brazil active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 118 Mexico active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 119 Mexico active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 120 Mexico active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 121 Mexico active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 122 Mexico active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 123 Argentina active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 124 Argentina active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 125 Argentina active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 126 Argentina active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 127 Argentina active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 128 Colombia active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 129 Colombia active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 130 Colombia active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 131 Colombia active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 132 Colombia active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 133 Chile active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 134 Chile active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 135 Chile active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 136 Chile active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 137 Chile active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 138 Middle East & Africa active pharmaceutical ingredient CDMO market, by country, 2018 - 2030 (USD Million)
Table 139 Middle East & Africa active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 140 Middle East & Africa active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 141 Middle East & Africa active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 142 Middle East & Africa active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 143 Middle East & Africa active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 144 South Africa active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 145 South Africa active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 146 South Africa active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 147 South Africa active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 148 South Africa active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 149 Saudi Arabia active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 150 Saudi Arabia active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 151 Saudi Arabia active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 152 Saudi Arabia active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 153 Saudi Arabia active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 154 UAE active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 155 UAE active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 156 UAE active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 157 UAE active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 158 UAE active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 159 Kuwait active pharmaceutical ingredient CDMO market, by product, 2018 - 2030 (USD Million)
Table 160 Kuwait active pharmaceutical ingredient CDMO market, by synthesis, 2018 - 2030 (USD Million)
Table 161 Kuwait active pharmaceutical ingredient CDMO market, by drug, 2018 - 2030 (USD Million)
Table 162 Kuwait active pharmaceutical ingredient CDMO market, by application, 2018 - 2030 (USD Million)
Table 163 Kuwait active pharmaceutical ingredient CDMO market, by workflow, 2018 - 2030 (USD Million)

※본 조사보고서 [글로벌 원료 의약품 CDMO 시장 (2023-2030) : 강력한 API, 항체 약물 접합체] (코드 : GRV23NOV025) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [글로벌 원료 의약품 CDMO 시장 (2023-2030) : 강력한 API, 항체 약물 접합체] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

세계의 저분자 이노베이터 CDMO 시장 (2023~2030) : 저분자 원료 의약품, 저분자 의약품 제품
GRV23MR035 / Grand View Research / 2023년 2월 / 미국 Grand View Research (그랜드뷰리서치)의 본 조사 보고서는 세계의 저분자 이노베이터 CDMO 시장 규모가 2023년부터 2030년 사이에 CAGR 6.4% 증가하여, 2030년에는 749억 달러에 이를 것으로 전망하고 있습니다. 본 자료는 세계의...Small Molecule Innovator CDMO Market Growth & Trends The global small molecule innovator CDMO market size is expected to reach USD 74.9 billion by 2030, expanding at 6.4% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. There is a growing interest among pharmaceutical...

글로벌 재조합 단백질 치료제 CDMO 시장 (2023-2030) : 성장 호르몬, 인터페론, 백신, 면역 자극제
GRV23NOV236 / Grand View Research / 2023년 9월 / 글로벌 재조합 단백질 치료제 CDMO 시장의 성장과 동향 Grand View Research사의 최신 보고서에 따르면, 세계의 재조합 단백질 치료제 CDMO 시장 규모는 2030년까지 519억 5000만 달러에 달할 것으로 예상되며, 2023년부터 2030년까지...Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변동, 동향, 범위 Chapter 4. 세계의 재조합 단백질 치료제 CDMO 시장 : 유형별 예측 및 동향 분석 Chapter 5. 세계의 재조합 단백질 치료제 CDMO 시장 : 공급원별 예측 및 동향 분석 Chapter 6. 세계의 재조합 단백질 치료제 CDMO...

글로벌 핵산 치료제 CDMO 시장 (2023-2030) : 프로세스 개발 및 최적화, 제조 서비스
GRV23NOV219 / Grand View Research / 2023년 9월 / 글로벌 핵산 치료제 CDMO 시장의 성장과 동향 Grand View Research사의 최신 보고서에 따르면, 세계의 핵산 치료제 CDMO 시장 규모는 2023년부터 2030년까지 연평균 9. 4%의 성장률을 보이며 2030년에는 224억 2000만 달러에...Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변동, 동향, 범위 Chapter 4. 세계의 핵산 치료제 CDMO 시장 : 유형별 예측 및 동향 분석 Chapter 5. 세계의 핵산 치료제 CDMO 시장 : 서비스별 예측 및 동향 분석 Chapter 6. 세계의 핵산 치료제 CDMO 시장 : 최종...

세계의 첨단 치료제 CDMO 시장 (2023-2030) : 유전자 치료, 세포 요법, 조직 공학
GRV23MA018 / Grand View Research / 2023년 1월 / 미국 Grand View Research (그랜드뷰리서치)는 세계의 첨단 치료제 CDMO 시장 규모가 2023년부터 2030년 사이에 연평균 18.8% 성장하여, 2030년에는 188억 달러에 달할 것으로 예측하고 있습니다. 본 조사 자료는 세계의 첨단 치료제...Advanced Therapy Medicinal Products CDMO Market Growth & Trends The global advanced therapy medicinal products CDMO market size is expected to reach USD 18.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.8% from 2023 to...

세계의 저분자 이노베이터 CDMO 시장 2024-2030 : 제품별 (저분자 API, 저분자 의약품), 단계별, 고객 유형별, 치료 영역별, 지역별
GRV24JAN134 / Grand View Research / 2023년 11월 / 글로벌 저분자 이노베이터 CDMO 시장의 성장과 동향 Grand View Research, Inc.사의 최신 보고서에 따르면,세계의 저분자 이노베이터 CDMO 시장 규모는 2030년까지 749억 달러에 달할 것으로 예상되며, 2024년부터 2030년까지 연평균 6.21%의 성장률을...1. 조사 방법 및 범위 2. 개요 3. 세계의 저분자 이노베이터 CDMO 시장 규모 : 변수, 동향 및 범위 4. 세계의 저분자 이노베이터 CDMO 시장 규모 : 제품별 세그먼트 분석 5. 세계의 저분자 이노베이터 CDMO 시장 규모 : 단계별 세그먼트 분석 6. 세계의 저분자 이노베이터 CDMO 시장 규모 : 고객...